TL;DR: FDA’s new Commissioner’s National Priority Voucher (CNPV) program accelerates reviews to ~1–2 months for products that advance U.S. national priorities: big-burden diseases, public-health crises, affordability, and on-shored manufacturing. If you’re heading into this pathway, success hinges on early CMC and labeling completeness, disciplined traceability, and an operating model built for rapid, team-based review. What’s inside the program Why it exists: Speed acce

Machine learning is transforming clinical trial monitoring from slow, manual oversight into real-time, predictive decision-making. As decentralized designs, digital biomarkers, and regulatory expectations evolve, the industry is entering a new era where data integrity, responsiveness, and automation are no longer optional—they’re essential.

Discover how EMA and FDA are transforming from reviewers to data-platform operators—and how sponsors and writers must adapt to real-time evidence exchange and continuous review.

Explore how the EMA’s 2025 Real-World Evidence Framework is reshaping regulatory submissions—and what it means for medical writers navigating structured data and evolving reviewer expectations.

Understanding AI Technologies AI technologies have made significant strides in recent years. Generative AI, in particular, has changed how we approach various tasks. From content creation to data analysis, AI is becoming an indispensable tool. However, to maximize its potential, we must understand the nuances of its operation. The Importance of AI in Biotech and Pharma In the biotech and pharmaceutical sectors, AI can streamline processes, enhance accuracy, and improve compli

In 2025, several major pharmaceutical companies — including MSD (Merck), AstraZeneca, and Eli Lilly — have scaled back or cancelled planned investments in the UK. Decisions have ranged from pausing vaccine-manufacturing expansions to abandoning research center projects.

Albert Einstein once said: “If you can’t explain it simply, you don’t understand it well enough.” Einstein’s words echo a principle at...

In clinical documentation, every word counts. One subtle yet powerful cognitive phenomenon that can shape how readers interpret and...

When I read McKinsey’s article, Rewiring Pharma’s Regulatory Submissions with AI and Zero-Based Design , I couldn’t help but feel a mix...

The biotech industry is buzzing with excitement following the FDA’s announcement of its Commissioner's National Priority Voucher (CNPV)...

AI-enabled medical writing significantly streamlines the clinical documentation process, but common pitfalls can reduce its...

Recent research from Microsoft offers one of the most comprehensive looks yet at how generative AI is already reshaping work activities...

Once Upon a Prompt In academic and clinical research, time is a precious commodity—and so is clarity. With artificial intelligence (AI) writing tools evolving at breakneck speed, researchers and medical writers are now asking a vital question:  How far can AI take us in crafting better, faster manuscripts?  The answer lies in the growing integration of AI-powered writing assistants and the complex terrain of ethics, journal policies, and return on investment (ROI). Let’s lo

As artificial intelligence becomes an increasingly powerful tool in regulatory and clinical writing, many professionals are eager to...

Using Speculative Fiction Techniques to Enhance Regulatory Submissions Speculative fiction is a broad genre of literature that explores...

In the realm of communication, whether it is a casual conversation, a persuasive speech, or a clinical study report, our words carry more...

When you align your writing with both your strengths and the world’s needs, you create more than just content - you create impact. In...

Discover how AI and structured content management are transforming regulatory submissions—boosting speed, consistency, and compliance in health authority interactions.

The FDA’s recent Evaluation of Labeling Submissions with AI (ELSA) pilot program has generated both curiosity and skepticism in the regulatory community. Early responses from reviewers using ELSA have been mixed, with some finding it helpful for catching inconsistencies or typos, while others found it redundant or disconnected from their workflows. While the effort is laudable, the ELSA pilot highlights deeper limitations in how general-purpose AI tools perform in complex, re

Integrating technology-assisted content reuse into medical writing can reduce stress for writers by preventing unnecessary rework and maintaining consistent document quality and compliance. This ensures timely delivery of important new therapies to the patients who need them.